ES2555381T3 - Moléculas biespecíficas de unión a EGFR/IGFIR - Google Patents
Moléculas biespecíficas de unión a EGFR/IGFIR Download PDFInfo
- Publication number
- ES2555381T3 ES2555381T3 ES09760433.4T ES09760433T ES2555381T3 ES 2555381 T3 ES2555381 T3 ES 2555381T3 ES 09760433 T ES09760433 T ES 09760433T ES 2555381 T3 ES2555381 T3 ES 2555381T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- egfr
- terminal extension
- tail
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title abstract description 113
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title abstract description 112
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title abstract description 112
- 230000027455 binding Effects 0.000 title abstract description 38
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 title description 18
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 title description 18
- 150000001413 amino acids Chemical class 0.000 abstract description 113
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 102000002090 Fibronectin type III Human genes 0.000 abstract 1
- 108050009401 Fibronectin type III Proteins 0.000 abstract 1
- 239000013636 protein dimer Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 description 119
- 235000001014 amino acid Nutrition 0.000 description 95
- 241000699666 Mus <mouse, genus> Species 0.000 description 60
- 239000003550 marker Substances 0.000 description 58
- 206010028980 Neoplasm Diseases 0.000 description 54
- 239000000178 monomer Substances 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 25
- 230000008859 change Effects 0.000 description 24
- 229960005395 cetuximab Drugs 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 19
- 239000004230 Fast Yellow AB Substances 0.000 description 18
- 229960001972 panitumumab Drugs 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 16
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 238000002513 implantation Methods 0.000 description 14
- 235000018417 cysteine Nutrition 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 11
- 102220347773 c.185C>G Human genes 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102200143234 rs121912767 Human genes 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical group CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 108010005942 methionylglycine Proteins 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 101100301828 Arabidopsis thaliana RH41 gene Proteins 0.000 description 4
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000005917 in vivo anti-tumor Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000003121 in-cell western assay Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101100118551 Mus musculus Egfr gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- SIIZPVYVXNXXQG-UQTMIEBXSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phos Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)O[C@H]2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-UQTMIEBXSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000994 contrast dye Substances 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 108700016418 rat Egfr Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US200164P | 2000-04-27 | ||
| US212966P | 2000-06-21 | ||
| US20016408P | 2008-11-24 | 2008-11-24 | |
| US20028208P | 2008-11-26 | 2008-11-26 | |
| US200282P | 2008-11-26 | ||
| US21296609P | 2009-04-17 | 2009-04-17 | |
| US17827909P | 2009-05-14 | 2009-05-14 | |
| US178279P | 2009-05-14 | ||
| US22733009P | 2009-07-21 | 2009-07-21 | |
| US227330P | 2009-07-21 | ||
| PCT/US2009/065765 WO2010060095A1 (en) | 2008-11-24 | 2009-11-24 | Bispecific egfr/igfir binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2555381T3 true ES2555381T3 (es) | 2015-12-30 |
Family
ID=41667546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09760433.4T Active ES2555381T3 (es) | 2008-11-24 | 2009-11-24 | Moléculas biespecíficas de unión a EGFR/IGFIR |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US8343501B2 (enExample) |
| EP (2) | EP2350126B1 (enExample) |
| JP (2) | JP5823870B2 (enExample) |
| KR (1) | KR20110098922A (enExample) |
| CN (1) | CN102439036B (enExample) |
| AR (1) | AR074399A1 (enExample) |
| AU (1) | AU2009316271A1 (enExample) |
| BR (1) | BRPI0922613A2 (enExample) |
| CA (1) | CA2744405A1 (enExample) |
| CL (1) | CL2011001214A1 (enExample) |
| CO (1) | CO6382161A2 (enExample) |
| EA (1) | EA022415B1 (enExample) |
| ES (1) | ES2555381T3 (enExample) |
| IL (1) | IL212715A0 (enExample) |
| MX (1) | MX2011005257A (enExample) |
| NZ (2) | NZ592782A (enExample) |
| PE (1) | PE20110587A1 (enExample) |
| TN (1) | TN2011000225A1 (enExample) |
| TW (1) | TWI496582B (enExample) |
| WO (1) | WO2010060095A1 (enExample) |
| ZA (1) | ZA201103766B (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2402567C2 (ru) | 2003-12-05 | 2010-10-27 | Бристоль-Майерз Сквибб Компани | Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2 |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| JP2011501951A (ja) | 2007-10-31 | 2011-01-20 | メディミューン，エルエルシー | タンパク質足場 |
| MX2010008874A (es) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. |
| US9296810B2 (en) | 2008-05-02 | 2016-03-29 | Novartis Ag | Fibronectin-based binding molecules and uses thereof |
| EP2291399B1 (en) | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| HRP20161251T1 (hr) | 2008-10-31 | 2016-11-18 | Janssen Biotech, Inc. | Platformski sastavi zasnovani na domeni fibronektina tipa iii, postupci i upotrebe |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| US8067201B2 (en) | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
| EP3434769B1 (en) | 2009-10-30 | 2020-11-25 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
| PE20130041A1 (es) | 2010-02-18 | 2013-01-28 | Bristol Myers Squibb Co | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) |
| AU2011240624B2 (en) | 2010-04-13 | 2017-02-23 | Medimmune, Llc | TRAIL R2-specific multimeric scaffolds |
| MX339126B (es) | 2010-04-30 | 2016-05-11 | Janssen Biotech Inc | Composiciones de dominio de fibronectina estabilizadas, metodos y usos. |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| ES2573108T3 (es) * | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada |
| JP2013533745A (ja) | 2010-07-06 | 2013-08-29 | ノバルティス アーゲー | ノロウイルスに由来する免疫原性組成物および方法 |
| AU2011283646B2 (en) * | 2010-07-30 | 2015-07-09 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
| CN106279433A (zh) * | 2011-03-04 | 2017-01-04 | 夏尔人类遗传治疗公司 | 用于多肽组成物的肽连接物及其使用方法 |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| SI2697257T1 (sl) | 2011-04-13 | 2017-02-28 | Bristol-Myers Squibb Company | FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| WO2012158739A1 (en) | 2011-05-17 | 2012-11-22 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
| IL277891B2 (en) | 2011-09-27 | 2024-01-01 | Janssen Biotech Inc | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| DK2771022T3 (da) | 2011-10-11 | 2020-09-28 | Viela Bio Inc | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf |
| JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
| WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| TW201843172A (zh) * | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| WO2014043344A1 (en) | 2012-09-13 | 2014-03-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| EP2951206A2 (en) * | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| EP2953968B1 (en) | 2013-02-06 | 2018-07-25 | Bristol-Myers Squibb Company | Fibronectin type iii domain proteins with enhanced solubility |
| ES2751735T3 (es) | 2013-02-12 | 2020-04-01 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| KR102478402B1 (ko) | 2013-10-14 | 2022-12-15 | 얀센 바이오테크 인코포레이티드 | 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자 |
| WO2015113494A1 (zh) * | 2014-01-28 | 2015-08-06 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| KR102472862B1 (ko) | 2014-03-20 | 2022-12-05 | 브리스톨-마이어스 스큅 컴퍼니 | 혈청 알부민-결합 피브로넥틴 유형 iii 도메인 |
| US10166273B2 (en) | 2014-08-12 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein |
| WO2016025645A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| EP4218832A3 (en) | 2014-11-25 | 2023-08-23 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain |
| CN114591420A (zh) | 2014-11-25 | 2022-06-07 | 百时美施贵宝公司 | 用于成像的新型pd-l1结合多肽 |
| CA2972800A1 (en) * | 2015-01-02 | 2016-07-07 | Dyax Corp. | Bispecific antibodies against plasma kallikrein and factor xii |
| AU2016297018B9 (en) | 2015-07-21 | 2022-12-01 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor XIIa |
| EP3353199B1 (en) | 2015-09-23 | 2020-02-19 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
| WO2017210302A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Pet imaging with pd-l1 binding polypeptides |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| EA201990067A1 (ru) | 2016-06-21 | 2019-07-31 | Янссен Байотек, Инк. | Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа |
| JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
| WO2018132516A1 (en) | 2017-01-10 | 2018-07-19 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator |
| US12331103B2 (en) | 2017-06-16 | 2025-06-17 | Protelica, Inc. | Fibronectin binding domain chimeric antigen receptors and methods of use thereof |
| WO2019036605A2 (en) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF |
| KR101943081B1 (ko) * | 2017-08-31 | 2019-01-29 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
| WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| US20200102370A1 (en) | 2018-09-28 | 2020-04-02 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| WO2020146706A2 (en) * | 2019-01-11 | 2020-07-16 | The University Of North Carolina At Chapel Hill | Highly modular biepitopic and bispecific car-t cells for cancer immunotherapy |
| KR101959020B1 (ko) * | 2019-01-14 | 2019-03-18 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
| US11235032B2 (en) | 2019-01-23 | 2022-02-01 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| US12491255B2 (en) | 2019-10-14 | 2025-12-09 | Aro Biotherapeutics Company | EPCAM binding fibronectin type III domains |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021202727A2 (en) | 2020-03-31 | 2021-10-07 | Repertoire Immune Medicines, Inc. | Barcodable exchangeable peptide-mhc multimer libraries |
| WO2022087154A1 (en) | 2020-10-20 | 2022-04-28 | Repertoire Immune Medicines, Inc. | Mhc class ii peptide multimers and uses thereof |
| US12239710B2 (en) | 2021-04-14 | 2025-03-04 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| EP4504246A1 (en) | 2022-04-07 | 2025-02-12 | Repertoire Immune Medicines, Inc. | T cell receptor multimers and uses thereof |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
| US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
| US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
| US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| ATE181732T1 (de) | 1989-04-19 | 1999-07-15 | Novo Nordisk As | Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| WO1992002536A1 (en) | 1990-08-02 | 1992-02-20 | The Regents Of The University Of Colorado | Systematic polypeptide evolution by reverse translation |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5773574A (en) | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
| US5235041A (en) | 1990-12-28 | 1993-08-10 | Protein Polymer Technologies, Inc. | Purification of structurally ordered recombinant protein polymers |
| US5792742A (en) | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
| AU2313392A (en) | 1991-08-01 | 1993-03-02 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
| AU673190B2 (en) | 1992-07-13 | 1996-10-31 | Bionebraska, Inc. | Method for modification of recombinant polypeptides |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| WO1994017097A1 (en) | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
| DK0654256T3 (da) | 1993-02-26 | 2000-12-18 | Santen Pharmaceutical Co Ltd | Bionedbrydelig senehindetampon |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5559000A (en) | 1995-01-18 | 1996-09-24 | The Scripps Research Institute | Encoded reaction cassette |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| DE19646372C1 (de) | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Genotyp und Phänotyp koppelnde Verbindung |
| GB9618960D0 (en) | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
| US5922676A (en) | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
| WO1998016636A1 (en) | 1996-10-17 | 1998-04-23 | Mitsubishi Chemical Corporation | Molecule that homologizes genotype and phenotype and utilization thereof |
| JP3837748B2 (ja) | 1997-01-17 | 2006-10-25 | 東亞合成株式会社 | Ｖｅｇｆ結合性ポリペプチド |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| CA2278786C (en) | 1997-01-21 | 2010-07-20 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
| EP0979102A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6159722A (en) | 1997-12-03 | 2000-12-12 | Boehringer Mannheim Gmbh | Chimeric serine proteases |
| US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
| US20030045681A1 (en) | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| JP4108827B2 (ja) | 1998-05-28 | 2008-06-25 | 大日本印刷株式会社 | 無機質系化粧板 |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP4562286B2 (ja) | 1998-12-10 | 2010-10-13 | ブリストル−マイヤーズ スクウィブ カンパニー | 抗体模倣物および他の結合タンパク質のタンパク質骨格 |
| GB9827228D0 (en) | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| CA2377468C (en) | 1999-07-27 | 2010-04-20 | Phylos, Inc. | Peptide acceptor ligation methods |
| US6399857B1 (en) | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| WO2001072829A2 (en) | 2000-03-31 | 2001-10-04 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| US20030104520A1 (en) | 2000-06-15 | 2003-06-05 | Ellington Andrew D. | Regulatable, catalytically active nucleic acids |
| JP4578768B2 (ja) | 2000-07-11 | 2010-11-10 | リサーチ コーポレイション テクノロジーズ，インコーポレイテッド | 人工抗体ポリペプチド |
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| US7598352B2 (en) | 2000-11-17 | 2009-10-06 | University Of Rochester | Method of identifying polypeptide monobodies which bind to target proteins and use thereof |
| ATE306951T1 (de) | 2000-11-29 | 2005-11-15 | Allergan Inc | Verhinderung von transplantatabstossung im auge |
| US6509027B2 (en) | 2001-02-12 | 2003-01-21 | Supergen, Inc. | Injectable pharmaceutical composition comprising coated particles of camptothecin |
| WO2002081497A2 (en) | 2001-04-04 | 2002-10-17 | University Of Rochester | αξβ3 INTEGRIN-BINDING POLYPEPTIDE MONOBODIES AND THEIR USE |
| US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
| US20030004561A1 (en) | 2001-06-28 | 2003-01-02 | Steve Bigus | Peeling sheath for self-expanding stent |
| AU2002342672A1 (en) | 2001-09-11 | 2003-03-24 | Nascacell Gmbh | Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes |
| US20080193445A1 (en) | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
| CN100346784C (zh) | 2002-02-22 | 2007-11-07 | 先灵公司 | 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途 |
| ES2362931T3 (es) | 2002-03-04 | 2011-07-15 | Imclone Llc | Anticuerpos humanos específicos contra kdr y usos de los mismos. |
| WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
| ATE517922T1 (de) | 2002-11-08 | 2011-08-15 | Ablynx Nv | Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation |
| US7053701B2 (en) | 2003-11-04 | 2006-05-30 | Vice Michael W | Power amplifier output stage with multiple power states and improved efficiency |
| CN102400990B (zh) | 2003-11-17 | 2014-08-20 | 远程接合技术公司 | 固定器组件 |
| US20080220049A1 (en) | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
| RU2402567C2 (ru) * | 2003-12-05 | 2010-10-27 | Бристоль-Майерз Сквибб Компани | Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2 |
| US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| MX2007003789A (es) | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
| EP1838307A1 (en) | 2004-12-02 | 2007-10-03 | Schering Corporation | Methods of using temozolomide formulation intrathecally in the treatment of cancers |
| BRPI0519897A2 (pt) | 2005-02-23 | 2009-08-18 | Merrimack Pharmaceuticals Inc | método para modular a atividade ou atividades biológicas de moléculas alvo em uma célula alvo, agente de ligação biespecìfico, composição, uso de um agente de ligação biespecìfico, e, kit |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7887273B2 (en) | 2005-09-15 | 2011-02-15 | Newfrey Llc | Blind rivet and method |
| US20070072933A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an ocular agent |
| CA2623687A1 (en) * | 2005-10-07 | 2007-04-19 | The Regents Of The University Of California | Nucleic acids encoding modified cytochrome p450 enzymes and methods of use thereof |
| CA2602577C (en) | 2005-10-18 | 2015-03-31 | Allergan, Inc. | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues |
| US20070099879A1 (en) | 2005-10-31 | 2007-05-03 | Wisconsin Alumni Research Foundation (Warf) | Method of using calcitriol for treating intraocular diseases associated with angiogenesis |
| ATE463512T1 (de) | 2005-11-09 | 2010-04-15 | Morphosys Ag | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern |
| RS58231B1 (sr) * | 2005-11-23 | 2019-03-29 | Acceleron Pharma Inc | Antagonisti aktivin-actriia i primene za stimulaciju rasta kostiju |
| EP2397148A3 (en) | 2006-02-02 | 2012-04-25 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
| CN101384279B (zh) * | 2006-02-24 | 2012-02-22 | 奇斯药制品公司 | 抗淀粉样蛋白免疫原性组合物、方法和用途 |
| KR20090005010A (ko) * | 2006-04-21 | 2009-01-12 | 트랜스진 에스.에이. | Ｈｐｖ-18-기재의 유두종바이러스 백신 |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| AU2007281774A1 (en) | 2006-08-04 | 2008-02-14 | Astrazeneca Ab | Human antibodies to ErbB 2 |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| US20110143953A1 (en) * | 2006-10-16 | 2011-06-16 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona | Synthetic Antibodies |
| AU2007325838B2 (en) * | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| US8476243B2 (en) * | 2006-12-29 | 2013-07-02 | Transderm, Inc. | Methods and compositions for treating keratin hyperproliferative disorders |
| WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
| EP2129397B1 (en) | 2007-03-02 | 2018-10-31 | Amgen, Inc. | Methods and compositions for treating tumor diseases |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| AU2008287426B2 (en) | 2007-08-10 | 2014-06-26 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| JP2010538972A (ja) | 2007-08-20 | 2010-12-16 | ブリストル−マイヤーズ スクイブ カンパニー | 転移性癌の処置のためのｖｅｇｆｒ−２阻害剤の使用 |
| EA201000343A1 (ru) | 2007-10-04 | 2011-10-31 | Займодженетикс, Инк. | ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ |
| JP2011501951A (ja) | 2007-10-31 | 2011-01-20 | メディミューン，エルエルシー | タンパク質足場 |
| WO2009073115A1 (en) | 2007-11-28 | 2009-06-11 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with mtor inhibitors |
| CA2709994A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Non-antibody scaffold protein fusions phage display via fusion to pix of m13 phage |
| WO2009083804A2 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| MX2010008874A (es) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. |
| US9296810B2 (en) | 2008-05-02 | 2016-03-29 | Novartis Ag | Fibronectin-based binding molecules and uses thereof |
| EP2291399B1 (en) | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
| HRP20161251T1 (hr) | 2008-10-31 | 2016-11-18 | Janssen Biotech, Inc. | Platformski sastavi zasnovani na domeni fibronektina tipa iii, postupci i upotrebe |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| WO2010069913A1 (en) | 2008-12-16 | 2010-06-24 | Novartis Ag | Yeast display systems |
| EP2396000A1 (en) | 2009-02-11 | 2011-12-21 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with temozolomide |
| EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| US8067201B2 (en) * | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
| US20120270797A1 (en) | 2009-08-13 | 2012-10-25 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| EP3434769B1 (en) | 2009-10-30 | 2020-11-25 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
| WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
| WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
| EP2533807A2 (en) | 2010-02-12 | 2012-12-19 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
| PE20130041A1 (es) | 2010-02-18 | 2013-01-28 | Bristol Myers Squibb Co | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) |
| AU2011240624B2 (en) | 2010-04-13 | 2017-02-23 | Medimmune, Llc | TRAIL R2-specific multimeric scaffolds |
| CN105175532B (zh) | 2010-04-13 | 2023-01-17 | 百时美施贵宝公司 | 结合pcsk9的基于纤连蛋白的支架域蛋白质 |
| MX339126B (es) | 2010-04-30 | 2016-05-11 | Janssen Biotech Inc | Composiciones de dominio de fibronectina estabilizadas, metodos y usos. |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| ES2573108T3 (es) | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada |
| AU2011283646B2 (en) | 2010-07-30 | 2015-07-09 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
| WO2012088006A1 (en) | 2010-12-22 | 2012-06-28 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind il-23 |
| SI2697257T1 (sl) | 2011-04-13 | 2017-02-28 | Bristol-Myers Squibb Company | FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| WO2012158739A1 (en) | 2011-05-17 | 2012-11-22 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
| IL277891B2 (en) | 2011-09-27 | 2024-01-01 | Janssen Biotech Inc | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
-
2009
- 2009-11-20 TW TW098139570A patent/TWI496582B/zh not_active IP Right Cessation
- 2009-11-24 CN CN200980155318.4A patent/CN102439036B/zh not_active Expired - Fee Related
- 2009-11-24 PE PE2011001073A patent/PE20110587A1/es not_active Application Discontinuation
- 2009-11-24 MX MX2011005257A patent/MX2011005257A/es active IP Right Grant
- 2009-11-24 WO PCT/US2009/065765 patent/WO2010060095A1/en not_active Ceased
- 2009-11-24 JP JP2011537719A patent/JP5823870B2/ja not_active Expired - Fee Related
- 2009-11-24 EP EP09760433.4A patent/EP2350126B1/en not_active Not-in-force
- 2009-11-24 AU AU2009316271A patent/AU2009316271A1/en not_active Abandoned
- 2009-11-24 CA CA2744405A patent/CA2744405A1/en not_active Abandoned
- 2009-11-24 BR BRPI0922613A patent/BRPI0922613A2/pt not_active IP Right Cessation
- 2009-11-24 EP EP15192336.4A patent/EP3029064A1/en not_active Withdrawn
- 2009-11-24 EA EA201100669A patent/EA022415B1/ru not_active IP Right Cessation
- 2009-11-24 NZ NZ592782A patent/NZ592782A/xx unknown
- 2009-11-24 NZ NZ601693A patent/NZ601693A/en unknown
- 2009-11-24 US US12/625,217 patent/US8343501B2/en active Active
- 2009-11-24 KR KR1020117014484A patent/KR20110098922A/ko not_active Ceased
- 2009-11-24 ES ES09760433.4T patent/ES2555381T3/es active Active
- 2009-11-24 AR ARP090104530A patent/AR074399A1/es unknown
-
2011
- 2011-05-05 IL IL212715A patent/IL212715A0/en unknown
- 2011-05-06 TN TN2011000225A patent/TN2011000225A1/fr unknown
- 2011-05-23 ZA ZA2011/03766A patent/ZA201103766B/en unknown
- 2011-05-24 CO CO11064214A patent/CO6382161A2/es active IP Right Grant
- 2011-05-24 CL CL2011001214A patent/CL2011001214A1/es unknown
-
2012
- 2012-12-03 US US13/692,555 patent/US9017655B2/en active Active
-
2015
- 2015-03-20 US US14/664,290 patent/US9771411B2/en active Active
- 2015-07-02 JP JP2015133521A patent/JP2016000731A/ja active Pending
-
2017
- 2017-08-23 US US15/684,595 patent/US10183987B2/en active Active
-
2018
- 2018-11-30 US US16/206,551 patent/US10954286B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2555381T3 (es) | Moléculas biespecíficas de unión a EGFR/IGFIR | |
| ES2953516T3 (es) | Proteínas de unión recombinantes y su uso | |
| US10774130B2 (en) | Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins | |
| ES2953482T3 (es) | Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica | |
| ES2879387T3 (es) | Proteínas de dominio de armazón a base de fibronectina que se unen a miostatina | |
| JP6410724B2 (ja) | 少なくとも２つの抗ｈｅｒ２反復ドメインを含む結合タンパク質 | |
| US20120270797A1 (en) | Engineered proteins including mutant fibronectin domains | |
| CN117120477A (zh) | 针对密蛋白18a2和cd3的双特异性抗体及其应用 | |
| AU2020414996A1 (en) | Method for producing eribulin-based antibody-drug conjugate | |
| RU2778346C2 (ru) | Рекомбинантные связывающие белки и их применение | |
| WO2025021993A1 (en) | Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof | |
| Kariolis | Combinatorial and Rational Approaches to Engineering Receptor-Based Antagonists of the Gas6/Axl System | |
| Igor et al. | The Native Structure of Annexin A2 Peptides in | |
| AU2013202605A1 (en) | Bispecific egfr/igfir binding molecules |